261
Participants
Start Date
December 4, 2012
Primary Completion Date
August 15, 2018
Study Completion Date
August 15, 2018
Idelalisib
150 mg tablets administered orally twice daily
Ofatumumab
Administered intravenously
Saint James's Hospital, Dublin
Cliniques Universitaires Saint Luc, Brussels
Prince of Wales Hospital, Randwick
Ziekenhuis Netwerk Antwerpen, Antwerp
Westmead Hospital, Westmead
Saint George and Sutherland Hospitals, Kogarah
Universitaire Ziekenhuis Gasthuisberg, Leuven
Box Hill Hospital, Box Hill
Frankston Hospital, Melbourne
Royal Brisbane and Women's Hospital, Herston
Haematology and Oncology Clinics of Australia at Mater, Milton
Queen Elizabeth Hospital, Woodville
Ashford Cancer Centre Research, Ashford
Aarhus University Hospital, Aarhus
Universitair Ziekenhuis Gent, Ghent
Aalborg Hospital, Aalborg
Weill Cornell Medical Center, New York
Center for Cancer and Blood Disorders, PC, Bethesda
Hospital Universitario La Princesa, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Puerta de Hierro Majadahonda, Madrid
Upstate Oncology Associates, Greenville
Hospital Morales Meseguer, Murcia
Georgia Regents University, Augusta
Centre Hospitalier Universitaire Purpan, Toulouse
Cancer Specialists of North Florida, Jacksonville
Center Hospitalier Universitaire de Bordeaux, Pessac
Tennessee Oncology, PLLC, Chattanooga
Montgomery Cancer Center, Mount Sterling
The Ohio State University Medical Center, Columbus
Oncology Hematology Care, Inc., Cincinnati
Centre Hospitalier Universitaire Nancy, Vandœuvre-lès-Nancy
CHRU Clermont- Ferrand CHU Estaing, Auvergne
Centre Hospitalier de Perpignan, Perpignan
Hôpital Saint Louis, Paris
Kaiser Permanente of Colorado, Denver
Saint Mary's Regional Cancer Center, Grand Junction
Utah Cancer Specialists, Salt Lake City
Comprehensive Cancer Centers of Nevada, Las Vegas
City of Hope, Duarte
Kaiser Permanente, San Diego
Centre Hospitalier Universitaire Hôpital Avicenne, Ile-de-france
Coastal Integrative Cancer Care, San Luis Obispo
California Cancer Associates for Research and Excellence (CCARE), Fresno
Stanford University Medical Center, Stanford
Kaiser Permanente Vallejo Medical Center, Vallejo
Oregon Health and Science University, Portland
Northwest Medical Specialties, Tacoma
Dana Farber Cancer Institute, Boston
Washington University Medical Center, St Louis
Tenessee Oncology, PLLC, Nashville
Tom Baker Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
Cancer Care Manitoba, Winnipeg
Cancer Care Manitoba, Winnipeg
Hopital Regional De Sudbury Regional Hospital (HRSRH) - Regional Cancer Program (RCP), Greater Sudbury
Centre Hospitalier Universitaire de Montréal, Montreal
Centre Hospitalier Regional de Rimouski, Rimouski
Saskatchewan Cancer Agency, Regina
University College Cork, Cork
Collegium Medicum Uniwersytetu Jagiellonskiego w K, Krakow
Wojewódzki Szpital Specjalistyczny im. Janusza Kor, Słupsk
Szpital Specjalistyczny w Brzozowie, Brzozów
Wojewódzki Szpital Specjalistyczny im. Mikolaja Kopernika w Lodzi, Lódz
Centralny Szpital Kliniczny MSW, Warsaw
Samodzielny Publiczny Szpital Kliniczny N1 Klinika, Wroclaw
Hospital Clínic i Provincial, Barcelona
Hospital Vall d´Hebrón, Barcelona
Sunderby Sjukhus, Luleå
Karolinska University Hospital Solna, Stockholm
Karolinska University Hospital Huddinge, Stockholm
Birmingham Heartlands Hospital, Birmingham
Darent Valley Hospital, Dartford
Royal Surrey County Hospital NHS Trust, Guildford
Haematology and Transplant Unit, Manchester
Norfolk and Norwich University Hospital, Norwich
Saint James's University Hospital, Leeds
University College London, London
University College London, London
Department of Haematology, Cancer and Haematology Centre, Churchill Hospital (Oxford University Hospitals), Oxford
Lead Sponsor
Gilead Sciences
INDUSTRY